Bio Gene Technology Stock Shares Owned By Insiders
| BGT Stock | 0.04 0 2.33% |
Bio Gene Technology fundamentals help investors to digest information that contributes to Bio Gene's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Gene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Gene stock.
Bio | Shares Owned By Insiders |
Bio Gene Technology Company Shares Owned By Insiders Analysis
Bio Gene's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Bio Gene Shares Owned By Insiders | 43.33 % |
Most of Bio Gene's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Gene Technology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 43.33% of Bio Gene Technology are shares owned by insiders. This is 185.44% higher than that of the Chemicals sector and 205.57% higher than that of the Materials industry. The shares owned by insiders for all Australia stocks is notably lower than that of the firm.
Bio Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Gene's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Gene could also be used in its relative valuation, which is a method of valuing Bio Gene by comparing valuation metrics of similar companies.Bio Gene is currently under evaluation in shares owned by insiders category among its peers.
Bio Fundamentals
| Return On Equity | -0.8 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 6.65 M | |||
| Shares Outstanding | 201.36 M | |||
| Shares Owned By Insiders | 43.33 % | |||
| Price To Book | 3.17 X | |||
| Price To Sales | 483.62 X | |||
| Revenue | 18.32 K | |||
| Gross Profit | 222.1 K | |||
| EBITDA | (2.97 M) | |||
| Net Income | (2.41 M) | |||
| Total Debt | 368.45 K | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (2.75 M) | |||
| Earnings Per Share | (0.01) X | |||
| Target Price | 0.37 | |||
| Beta | 0.71 | |||
| Market Capitalization | 8.86 M | |||
| Total Asset | 3.16 M | |||
| Retained Earnings | (19.64 M) | |||
| Working Capital | 2.59 M | |||
| Net Asset | 3.16 M |
About Bio Gene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Gene Technology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Gene Technology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bio Stock Analysis
When running Bio Gene's price analysis, check to measure Bio Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Gene is operating at the current time. Most of Bio Gene's value examination focuses on studying past and present price action to predict the probability of Bio Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Gene's price. Additionally, you may evaluate how the addition of Bio Gene to your portfolios can decrease your overall portfolio volatility.